Alembic Pharmaceuticals Ltd.

is an Indian multinational pharmaceutical company

headquartered in Vadodara city of Gujarat – India. Alembic Pharmaceuticals Ltd. is involved
in manufacture of pharmaceutical products, pharmaceutical substances and intermediates.
It is also termed to be a market leader in macrolides segment of anti-infective drugs in India.

The company has its headquarters and Corporate Office situated in Vadodara, Gujarat –
India while its manufacturing facilities are located at Panelav, Karakhadi in Gujarat and
Sikkim, India. Its Panelav plant houses active pharmaceutical ingredients (APIs) and
formulation manufacturing, while its Sikkim plant is involved in manufacture of formulations
for Indian and non-regulated export markets.

Alembic Pharmaceuticals Ltd. initially began as Alembic Chemical Works where it started
manufacturing tincture and alcohol at its unit at Vadodara in 1907. The company eventually
entered into manufacturing cough syrups, vitamins, tonics and sulphur drugs. Further,
Alembic entered into production of penicillin in the 1960s. This dedicated Alembic plant for
the manufacture of penicillin was inaugurated by Lal Bahadur Shastri in the year 1961, the
then Prime Minister of India. Alembic soon also initiated bulk production of vitamin B12. In
the antibiotic section, soon after initiation of penicillin manufacture, Alembic began the
production of erythromycin in 1971 for first time in India. Alembic also incorporated and
launched the 'Althrocin' brand of erythromycin. In the year, 1997, Althrocin became the top
selling brand of erythromycin in India. In 2000, Alembic received ISO 14000 certification for
its Vadodara facility. In 2010, Alembic Pharmaceutical Ltd. demerged from Alembic Ltd.
subsequent to the allotment of 133,515,914 equity shares of ₹2 each to the shareholders of
Alembic Ltd. This made the shareholding of Alembic Ltd. in Alembic Pharmaceutical to
reduce from 100% to 29.18%. In 2011, the equity shares of Alembic Pharmaceuticals Ltd.
were listed on the Bombay Stock Exchange and National Stock Exchange of India.
Mr. Chirayu Amin

Chairman & CEO

Mr. Chirayu Amin, the chairman of the Alembic group, has played a pivotal role in the
growth of the organization. Being an MBA from the United States, Mr. Amin has well
adapted to the changing needs of modern day business while keeping intact the legacy of
more than 100 years. Along with being the chairman of all Alembic group businesses, he
also holds the trusteeship in the hospital and schools that fall under the aegis of Alembic
Group.

Mr. Pranav Amin

Managing Director

Mr. Pranav Amin is the Managing Director of Alembic Pharmaceuticals Ltd. and heads the
International Business Unit of the Organization. He joined the organization in 2007 as a
Director and was elevated to the position of Joint Managing Director in 2015. In April 2016,
he took charge as a Managing Director. A graduate in Economics/Industrial Management
from the Carnegie Mellon University in Pittsburgh, USA and MBA in International
Management from Thunderbird, Arizona State, USA, he is a great people leader and leads
his enterprise through involvement, empowerment, and autonomy. He is also a Trustee of
the Bhailal Amin General Hospital and the Uday Education Society, a trust which runs four
schools in Vadodara.

Mr. Shaunak Amin

Managing Director

Mr. Shaunak Amin has graduated from University of Massachusetts, USA with Economics as
his specials. He has varied work experience with renowned multinationals including Merril
Lynch, Hong Kong and Shanghai Banking Corporation, etc. His extensive experience in Sales
and Marketing has benefited the Company immensely in achieving the new heights in sales.

Mr. K. G. Ramanathan

Independent Director
Mr. K. G. Ramanathan is a postgraduate in Physics from University of Madras and is a retired
IAS Officer. He has worked in senior administrative positions with the Government of
Gujarat and Government of India. He has wide industrial experience particularly in the fields
of fertilizers, chemicals and petrochemicals. Before his retirement from government service,
he was the Chairman and Managing Director of Indian Petrochemicals Corporation Limited
(IPCL), a prestigious petrochemical Company of India. Mr. Ramanathan is the Chairman of
Chemical and Petrochemical Manufacturers Association of India. He is also the founder
President of Indian Centre for Plastics in the Environment (ICPE).

Strengths:

• Stocks where Mutual Funds Increased Holdings in Past Month

• Rising Net Cash Flow and Cash from Operating activity
• Stocks with improving cash flow, with good durability
• Effectively using its capital to generate profit - RoCE improving in last 2 years
• Efficient in managing Assets to generate Profits - ROA improving since last 2 year
• Company with Low Debt
• Annual Net Profits improving for last 2 years
• Book Value per share Improving for last 2 years
• Company with Zero Promoter Pledge
• MFs increased their shareholding last quarter

Weakness:

• Negative Breakdown Second Support (LTP < S2)

• Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
• Lowest Momentum Scores (Technical Scores)
• Decline in Net Profit with falling Profit Margin (QoQ)
• Decline in Quarterly Net Profit with falling Profit Margin (YoY)
• Declining profits every quarter for the past 3 quarters
• Fall in Quarterly Revenue and Net Profit (YoY)
• Near 52 Week Low
• Weak Momentum: Price below Short, Medium and Long Term Averages
Opportunities:

• Buy Zone: Stocks in the buy zone based on days traded at current PE and P/BV
• Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
• Rising Delivery Percentage Compared to Prev Day

Threats:

• Companies with high market cap, lower public shareholding

• Stocks with Expensive Valuations according to the Trendlyne Valuation Score

DR. Reddy’s Laboratories:

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company located in

Hyderabad, Telangana, India. The company was founded by Anji Reddy, who previously

worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's

manufactures and markets a wide range of pharmaceuticals in India and overseas. The

company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug

manufacture, diagnostic kits, critical care, and biotechnology products. Dr. Reddy's began as

a supplier to Indian drug manufacturers, but it soon started exporting to other

less regulated markets that had the advantage of not having to spend time and money on a

manufacturing plant that would gain approval from a drug licensing body such as the U.S.

Food and Drug Administration (FDA).

Glenmark Pharmaceuticals:

Glenmark was founded with a vision to emerge as a leading integrated research-based,

global pharmaceutical company with an average market capitalization of 9174.54cr. as on

21st June 2021. Their branded generics business has a significant presence in markets across
emerging economies including India with its total revenue of 10640cr and their current ratio

is 1.65 (>1). The generics business services the requirements of developed markets like the

US and Western Europe. Their API business sells products in over 65 countries including the

US, various countries in the EU, South America, and India .With 14 manufacturing facilities

and 3 R&D centers dedicated to the goal of enriching lives across the globe we believe that

the real force behind our continued successes is dedicated employees from across 60

nationalities, committed to creating 'A new way for a new world'.

Alembic Pharma, which had traditionally focused on generic drugs, into the area of

discovery research. It has a strong presence in a few other countries. The company's stock

price has plummeted, and the management is under pressure from financial analysts to

drop discovery research and focus on what they had always done best generics. This

company will surely achieve its desired objectives and targets, will be in the top position of

pharmaceutical markets.